Enhanced Oral Bioavailability and Gastroprotective Effect of Ibuprofen Through Mixed Polymer–Lipid Nanoparticles

Abstract

Objectives: The aim of this study was to design and formulate mixed polymer–lipid nanoparticles (PLNs) for the delivery of ibuprofen. Methods: The mixed PLNs were prepared by a single modified emulsification solvent evaporation method. Key findings: Core-shell-shaped mixed PLNs were successfully prepared, with sizes in the nano range (193.3 ± 0.70 to 795.8 ± 0.70 nm) and ζ potential (−26.8 ± 0.45 to −42.8 ± 0.30 mV). Entrapment efficiency ranged from 80.3 to 93.6%. Conclusions: Pharmacokinetic parameters showed great improvement in C_max and T_max of ibuprofen from the formulation PLNs8 compared with the respective Brufen^® and pure drugs, indicating improvement in bioavailability of the drug.

Graphical abstract

Keywords:

• Box–Behnken design
• ibuprofen
• PLGA
• poly(lactic-co-glycolic acid)
• polymer–lipid nanoparticles
• Wistar rats

Supplementary data

To view the supplementary data that accompany this paper please visit the journal website at:www.futurescience.com/doi/suppl/10.2144/tde-2020-0125

Financial & competing interests disclosure

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

No writing assistance was utilized in the production of this manuscript.

Ethical conduct of research

The research protocol and animal care guidelines [201703MA2] were accepted by the institution’s research ethics committee at Faculty of Pharmacy, Suez Canal University. The NIH guidelines for use and care of laboratory animals (8th edition) were followed during the study. The authors state that they have obtained appropriate institutional review board approval or have followed the principles outlined in the Declaration of Helsinki for all human or animal experimental investigations.